These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23250968)

  • 1. Beyond indications: postmarket surveillance and the importance of expanded and off-label use of transcatheter devices in structural and congenital interventions.
    McElhinney DB
    Circ Cardiovasc Interv; 2012 Dec; 5(6):739-40. PubMed ID: 23250968
    [No Abstract]   [Full Text] [Related]  

  • 2. Transcatheter device closure of atrial septal defects: a safety review.
    Moore J; Hegde S; El-Said H; Beekman R; Benson L; Bergersen L; Holzer R; Jenkins K; Ringel R; Rome J; Vincent R; Martin G;
    JACC Cardiovasc Interv; 2013 May; 6(5):433-42. PubMed ID: 23702008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The off-versus on-label use of medical devices in interventional cardiovascular medicine?: Clarifying the ambiguity between regulatory labeling and clinical decision making, part III: structural heart disease interventions.
    Holzer R; Hijazi Z
    Catheter Cardiovasc Interv; 2008 Nov; 72(6):848-52. PubMed ID: 19006259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use: an industry perspective on expanding use beyond approved indications.
    Russell ME; Friedman MI; Mascioli SR; Stolz LE
    J Interv Cardiol; 2006 Oct; 19(5):432-8. PubMed ID: 17020568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US and European postmarket clinical data requirements.
    Donawa M
    Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of proactive medical device surveillance: the VA Clinical Assessment Reporting and Tracking (CART) program.
    Tsai TT; Box TL; Gethoffer H; Noonan G; Varosy PD; Maddox TM; Fihn SD; Gross TP; Jesse RL; Rumsfeld JS
    Med Care; 2013 Mar; 51(3 Suppl 1):S57-61. PubMed ID: 23407013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric therapeutic cardiac catheterization: a statement for healthcare professionals from the Council on Cardiovascular Disease in the Young, American Heart Association.
    Allen HD; Beekman RH; Garson A; Hijazi ZM; Mullins C; O'Laughlin MP; Taubert KA
    Circulation; 1998 Feb; 97(6):609-25. PubMed ID: 9494035
    [No Abstract]   [Full Text] [Related]  

  • 10. Erosions, erosions, and erosions! Device closure of atrial septal defects: how safe is safe?
    Diab K; Kenny D; Hijazi ZM
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):168-74. PubMed ID: 22718680
    [No Abstract]   [Full Text] [Related]  

  • 11. Probing the safety of central venous catheters.
    Murray EW
    Am J Nurs; 1993 May; 93(5):72, 75-6. PubMed ID: 8488905
    [No Abstract]   [Full Text] [Related]  

  • 12. Beyond the US submisson process.
    Donawa M
    Med Device Technol; 2004 Apr; 15(3):30-2. PubMed ID: 15255536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
    [No Abstract]   [Full Text] [Related]  

  • 14. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarket surveillance for medical devices: America's new strategy.
    Normand SL; Hatfield L; Drozda J; Resnic FS
    BMJ; 2012 Oct; 345():e6848. PubMed ID: 23060660
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Package insert of shunt closure devices, for the doctor or for the lawyer?
    Meier B
    Catheter Cardiovasc Interv; 2009 May; 73(6):827. PubMed ID: 19367650
    [No Abstract]   [Full Text] [Related]  

  • 19. The "art" of medicine and the "smokescreen" of the randomized trial off-label use of vascular devices.
    Ansel GM; Jaff MR
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):998-1002. PubMed ID: 19021289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.